COVID-19-associated fungal infections

M Hoenigl, D Seidel, R Sprute, C Cunha… - Nature …, 2022 - nature.com
Abstract Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an
important complication in a substantial number of critically ill, hospitalized patients with …

The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin

M Hoenigl, R Sprute, M Egger, A Arastehfar… - Drugs, 2021 - Springer
The epidemiology of invasive fungal infections is changing, with new populations at risk and
the emergence of resistance caused by the selective pressure from increased usage of …

[HTML][HTML] Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European …

J Prattes, J Wauters, DR Giacobbe… - Clinical Microbiology …, 2022 - Elsevier
Abstract Objectives Coronavirus disease 2019 (COVID-19)-associated pulmonary
aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The …

Microbe‐Mediated Biosynthesis of Multidimensional Carbon‐Based Materials for Energy Storage Applications

S Shen, Y Chen, J Zhou, H Zhang, X Xia… - Advanced Energy …, 2023 - Wiley Online Library
Biosynthesis methods are considered to be a promising technology for engineering new
carbon‐based materials or redesigning the existing ones for specific purposes with the aid …

CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models

M Seif, TK Kakoschke, F Ebel, MM Bellet… - Science Translational …, 2022 - science.org
Aspergillus fumigatus is a ubiquitous mold that can cause severe infections in
immunocompromised patients, typically manifesting as invasive pulmonary aspergillosis …

Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study

S Hatzl, AC Reisinger, F Posch, J Prattes, M Stradner… - Critical Care, 2021 - Springer
Abstract Background Coronavirus disease 19 (COVID-19)-associated pulmonary
aspergillosis (CAPA) emerged as important fungal complications in patients with COVID-19 …

The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey

J Salmanton-García, M Hoenigl, JP Gangneux… - The Lancet …, 2023 - thelancet.com
Access to the appropriate tools is crucial for early diagnosis and clinical management of
invasive fungal infections. This Review aims to describe the invasive fungal infection …

[HTML][HTML] Impact of climate change and natural disasters on fungal infections

D Seidel, S Wurster, JD Jenks, H Sati… - The Lancet …, 2024 - thelancet.com
The effects of climate change and natural disasters on fungal pathogens and the risks for
fungal diseases remain incompletely understood. In this literature review, we examined how …

[HTML][HTML] The changing epidemiology of fungal infections

C Lass-Flörl, S Steixner - Molecular Aspects of Medicine, 2023 - Elsevier
Invasive fungal diseases are common complications in critically ill patients and in those with
significant underlying imbalanced immune systems. Fungal co-, and/or super-infections are …

Prevalence of COVID-19-associated pulmonary aspergillosis: critical review and conclusions

M Egger, L Bussini, M Hoenigl, M Bartoletti - Journal of Fungi, 2022 - mdpi.com
First reports of cases and case series of COVID-19-associated pulmonary aspergillosis
(CAPA) emerged during the first months of the pandemic. Prevalence rates varied widely …